American Century Companies Inc. Has $14.30 Million Stock Position in Cytokinetics, Incorporated $CYTK

American Century Companies Inc. raised its position in Cytokinetics, Incorporated (NASDAQ:CYTK) by 19.7% during the second quarter, HoldingsChannel.com reports. The firm owned 432,731 shares of the biopharmaceutical company’s stock after buying an additional 71,343 shares during the quarter. American Century Companies Inc.’s holdings in Cytokinetics were worth $14,298,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CYTK. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. raised its position in shares of Cytokinetics by 571.2% in the second quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 1,082,563 shares of the biopharmaceutical company’s stock valued at $35,768,000 after purchasing an additional 921,278 shares during the period. Paradigm Biocapital Advisors LP acquired a new position in Cytokinetics in the 1st quarter valued at $34,510,000. Nuveen LLC bought a new position in Cytokinetics in the 1st quarter worth $14,121,000. Aberdeen Group plc lifted its position in Cytokinetics by 53.2% during the 2nd quarter. Aberdeen Group plc now owns 922,929 shares of the biopharmaceutical company’s stock worth $30,494,000 after acquiring an additional 320,508 shares during the last quarter. Finally, Vestal Point Capital LP boosted its holdings in Cytokinetics by 10.2% during the first quarter. Vestal Point Capital LP now owns 2,590,531 shares of the biopharmaceutical company’s stock valued at $104,113,000 after acquiring an additional 240,531 shares during the period.

Cytokinetics Stock Up 1.8%

Cytokinetics stock opened at $64.66 on Thursday. The business has a 50 day moving average price of $61.25 and a two-hundred day moving average price of $45.88. Cytokinetics, Incorporated has a 12 month low of $29.31 and a 12 month high of $69.33. The stock has a market cap of $7.91 billion, a price-to-earnings ratio of -10.28 and a beta of 0.58.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.05. The firm had revenue of $1.94 million for the quarter, compared to the consensus estimate of $6.05 million. The business’s revenue for the quarter was up 318.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.36) earnings per share. On average, analysts expect that Cytokinetics, Incorporated will post -5.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Wall Street Zen lowered Cytokinetics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Citigroup raised their target price on Cytokinetics from $77.00 to $84.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a report on Tuesday, October 21st. Stifel Nicolaus increased their price objective on Cytokinetics from $87.00 to $96.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Finally, Evercore ISI raised their price objective on shares of Cytokinetics from $60.00 to $80.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 3rd. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cytokinetics presently has a consensus rating of “Moderate Buy” and a consensus target price of $79.29.

Insider Activity

In other Cytokinetics news, Director Robert Arthur Harrington sold 2,150 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $66.80, for a total value of $143,620.00. Following the sale, the director owned 18,542 shares of the company’s stock, valued at $1,238,605.60. The trade was a 10.39% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John T. Henderson sold 8,750 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The stock was sold at an average price of $63.90, for a total transaction of $559,125.00. Following the transaction, the director directly owned 74,578 shares of the company’s stock, valued at $4,765,534.20. The trade was a 10.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 101,766 shares of company stock valued at $6,273,298. 2.70% of the stock is owned by insiders.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.